Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eiichi Shiba

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Breast Cancer (Tokyo, Japan)|February 7, 2015
A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancerEiichi Shiba, Hiroko Yamashita, Junichi Kurebayashi, et al.
Cancer Science|June 29, 2019
Different sensitivities of senescent breast cancer cells to immune cell-mediated cytotoxicityTouko Inao, Hitoshi Kotani, Yuichi Iida, et al.
Anticancer Research|May 23, 2002
uPA receptor expression in benign and malignant thyroid tumorsSeung Jin Kim, Eiichi Shiba, Tetsuya Taguchi, et al.
Cancer Chemotherapy and Pharmacology|July 21, 2007
Capecitabine and paclitaxel combination chemotherapy for inoperable or recurrent breast cancer: a phase I dose-finding study by the Kinki Breast Cancer Study GroupNorikazu Masuda, Tetsuya Taguchi, Takahiro Nakayama, et al.
Breast Cancer (Tokyo, Japan)|February 27, 2021
A follow-up study of a randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-month depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancerJunichi Kurebayashi, Eiichi Shiba, Tatsuya Toyama, et al.
Oncology|October 2, 2019
Prognostic Factors in HER2-Positive Primary Breast Cancer Patients Treated Using Neoadjuvant Chemotherapy Plus TrastuzumabNoriko Fujita, Yukie Enomoto, Keiko Inakami, et al.
Anticancer Research|July 28, 2004
Combination chemotherapy with docetaxel and doxifluridine showed a beneficial outcome in advanced or recurrent breast cancer patients with longer disease-free intervalReiki Nishimura, Takeshi Tominaga, Shoshu Mitsuyama, et al.
Oncology|February 3, 2022
Response-Guided Omission of Anthracycline in Patients with HER2-Positive Early Breast Cancer Treated with Neoadjuvant Taxane and Trastuzumab: 5-Year Follow-Up of Prognostic Study Using Propensity Score MatchingNoriko Fujita, Koichi Fujita, Seung Jin Kim, et al.
Journal of Medical Case Reports|April 30, 2024
Pembrolizumab response in stage IV luminal-type breast cancer with high microsatellite instability: a case reportKeiko Inakami, Noriko Fujita, Chikage Iguchi, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Breast Cancer (Tokyo, Japan)|February 7, 2015
A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancerEiichi Shiba, Hiroko Yamashita, Junichi Kurebayashi, et al.
Cancer Science|June 29, 2019
Different sensitivities of senescent breast cancer cells to immune cell-mediated cytotoxicityTouko Inao, Hitoshi Kotani, Yuichi Iida, et al.
Anticancer Research|May 23, 2002
uPA receptor expression in benign and malignant thyroid tumorsSeung Jin Kim, Eiichi Shiba, Tetsuya Taguchi, et al.
Cancer Chemotherapy and Pharmacology|July 21, 2007
Capecitabine and paclitaxel combination chemotherapy for inoperable or recurrent breast cancer: a phase I dose-finding study by the Kinki Breast Cancer Study GroupNorikazu Masuda, Tetsuya Taguchi, Takahiro Nakayama, et al.
Breast Cancer (Tokyo, Japan)|February 27, 2021
A follow-up study of a randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-month depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancerJunichi Kurebayashi, Eiichi Shiba, Tatsuya Toyama, et al.
Oncology|October 2, 2019
Prognostic Factors in HER2-Positive Primary Breast Cancer Patients Treated Using Neoadjuvant Chemotherapy Plus TrastuzumabNoriko Fujita, Yukie Enomoto, Keiko Inakami, et al.
Anticancer Research|July 28, 2004
Combination chemotherapy with docetaxel and doxifluridine showed a beneficial outcome in advanced or recurrent breast cancer patients with longer disease-free intervalReiki Nishimura, Takeshi Tominaga, Shoshu Mitsuyama, et al.
Oncology|February 3, 2022
Response-Guided Omission of Anthracycline in Patients with HER2-Positive Early Breast Cancer Treated with Neoadjuvant Taxane and Trastuzumab: 5-Year Follow-Up of Prognostic Study Using Propensity Score MatchingNoriko Fujita, Koichi Fujita, Seung Jin Kim, et al.
Journal of Medical Case Reports|April 30, 2024
Pembrolizumab response in stage IV luminal-type breast cancer with high microsatellite instability: a case reportKeiko Inakami, Noriko Fujita, Chikage Iguchi, et al.
Pageof 2